Vaxxinity Inc
OTC:VAXX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
GEA Group AG
XETRA:G1A
|
DE |
|
I
|
IWS Group Holdings Ltd
HKEX:6663
|
HK |
|
Xin Point Holdings Ltd
HKEX:1571
|
CN |
Vaxxinity Inc
Stock-Based Compensation
Vaxxinity Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Vaxxinity Inc
OTC:VAXX
|
Stock-Based Compensation
$7.5m
|
CAGR 3-Years
95%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Stock-Based Compensation
$955m
|
CAGR 3-Years
12%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Stock-Based Compensation
$894m
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Stock-Based Compensation
$494m
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Stock-Based Compensation
$685.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Stock-Based Compensation
$993.7m
|
CAGR 3-Years
11%
|
CAGR 5-Years
18%
|
CAGR 10-Years
8%
|
|
Vaxxinity Inc
Glance View
Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company is headquartered in Dallas, Texas and currently employs 89 full-time employees. The company went IPO on 2021-11-11. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) enables a new class of therapeutics that will improve the access to treatments for a range of indications. Its Vaxxine Platform is designed to connect the immune system to convert the body into its own drug factory, stimulating the production of antibodies with a therapeutic or protective effect. Its technology uses synthetic peptides to mimic and optimally combine biological epitopes in order to selectively activate the immune system, producing antibodies against only the desired targets, including self-antigens, making possible the safe and effective treatment of chronic diseases by vaccines. The modular and synthetic nature of its Vaxxine Platform provides significant in candidate development and has generated multiple product candidates that it is designing for many chronic diseases.
See Also
What is Vaxxinity Inc's Stock-Based Compensation?
Stock-Based Compensation
7.5m
USD
Based on the financial report for Dec 31, 2023, Vaxxinity Inc's Stock-Based Compensation amounts to 7.5m USD.
What is Vaxxinity Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 3Y
95%
Over the last year, the Stock-Based Compensation growth was -14%. The average annual Stock-Based Compensation growth rates for Vaxxinity Inc have been 95% over the past three years .